Strictly Buy and Sell Set Ups Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Strictly Buy and Sell Set Ups

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: - with a K who wrote (2353)	2/22/2005 8:39:36 PM
From: - with a K	Read Replies (2) of 13449

IPXL in Forbes story on acquisition possibility. It finished up 7.13%, and still strong TRLG was up 2.86% EZA gapped up on nice volume, up 3.45% The rest of my portfolio is filled with red, but these three help. Glad I sold CHS and a few others. Potential Takeover Targets In Specialty Pharma 02.22.05, 4:20 PM ET Credit Suisse First Boston expects merger activity to intensify in the specialty pharmaceuticals sector after Novartis (nyse: NVS - news - people ) said it would buy Eon Labs (nasdaq: ELAB - news - people ) and Hexal for $8.3 billion. "We believe these acquisitions could signal the start of further consolidation in the generics sector," said CSFB. "To the extent Novartis' actions trigger further M&A in the sector, we believe Impax Laboratories (nasdaq: IPXL - news - people ), and to a lesser extent, Watson Pharmaceuticals (nyse: WPI - news - people ), remain attractive consolidation targets in the context of the Eon Labs takeover." CSFB said Impax Labs possesses an attractive flow of new products while Watson has favorable valuation attributes.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next